Trial results

Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide

NCT07777575 on ClinicalTrials.gov · last registry update 2026-08-20

An unusually large phase 4: 150 participants, more than double the 72 typical for the stage. Due to report 31 May 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change in contractile thigh muscle volume (mL), as assessed by magnetic resonance imaging (MRI). Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P4

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Technical University of Munich

Sponsor type

Other

Enrollment

150

Started

2026-08-17

Primary completion

2027-05-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in contractile thigh muscle volume (mL), as assessed by magnetic resonance imaging (MRI)

Conditions studied

Obesity (BMI>30)

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.